Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.

DUBLIN and PHILADELPHIA, July 8, 2010 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that its subsidiaries Shire Development
Inc. and Shire Pharmaceutical Development Inc. have filed a lawsuit in the
U.S. District Court for the District of Delaware against Cadila Healthcare
Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
(collectively "Zydus") for the infringement of U.S. Patent No. 6,773,720 (the
'720 patent).

The lawsuit was filed as a result of an Abbreviated New Drug Application
(ANDA) filed by Zydus seeking FDA approval to market and sell generic
versions of Lialda(R) (mesalamine) prior to the expiration of the '720
patent.

Under the Hatch-Waxman Act, because Shire filed its patent infringement
lawsuit within 45 days of receiving the Paragraph IV notification letter from
Zydus, the FDA must refrain from approving Zydus' ANDA for 30 months, or
until a district court decision finding that the patent is invalid or not
infringed, whichever occurs earlier. The stay on generic approval will expire
in November 2012 unless terminated earlier.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty
biopharmaceutical company that focuses on meeting the needs of the specialist
physician. Shire focuses its business on attention deficit hyperactivity
disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)
diseases as well as opportunities in other therapeutic areas to the extent
they arise through acquisitions. Shire's in-licensing, merger and acquisition
efforts are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes that a
carefully selected and balanced portfolio of products with strategically
aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:
www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995

Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve a number
of risks and uncertainties and are subject to change at any time. In the
event such risks or uncertainties materialize, the Company's results could be
materially adversely affected. The risks and uncertainties include, but are
not limited to, risks associated with: the inherent uncertainty of research,
development, approval, reimbursement, manufacturing and commercialization of
the Company's Specialty Pharmaceutical and Human Genetic Therapies products,
as well as the ability to secure and integrate new products for
commercialization and/or development; government regulation of the Company's
products; the Company's ability to manufacture its products in sufficient
quantities to meet demand; the impact of competitive therapies on the
Company's products; the Company's ability to register, maintain and enforce
patents and other intellectual property rights relating to its products; the
Company's ability to obtain and maintain government and other third-party
reimbursement for its products; and other risks and uncertainties detailed
from time to time in the Company's filings with the Securities and Exchange
Commission.

For further information please contact:

    Investor         Clea Rosenfeld (Rest of the World)   +44(0)1256-894-160
    Relations        Eric Rojas (North America)           +1-781-482-0999

    Media            Jessica Mann (Rest of the World)     +44(0)1256-894-280
                     Matthew Cabrey (North America,       +1-484-595-8248
                     Specialty Pharma)

For further information please contact: Investor Relations: Clea Rosenfeld (Rest of the World) +44(0)1256-894-160, Eric Rojas (North America) +1-781-482-0999; Media: Jessica Mann (Rest of the World) +44(0)1256-894-280, Matthew Cabrey (North America, Specialty Pharma) +1-484-595-8248